Artivion (AORT) director Ackerman received 7,576 shares
Insider transactions reported
Thomas F Ackerman (director at Artivion Inc., AORT) reported that they received 7,576 shares on May 18, 2026. After these transactions the filing shows 157,472 shares held directly.
- Reporting person
- Ackerman Thomas F
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| May 18, 2026 | Grant or award (A) | Common Stock1 | +7,576 | - | - | 157,472 direct |
Holdings before and after
- Common Stock: 149,896 to 157,472 direct
Footnotes from the filing
- 1. RSA Grant vests on May 18, 2027, pursuant to the terms of the Equity and Cash Incentive Plan.
Transaction codes in this filing
- Grant or award:
- Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
FAQ
What did Ackerman report in this AORT Form 4?
Thomas F Ackerman (director at Artivion Inc., AORT) reported that they received 7,576 shares on May 18, 2026. After these transactions the filing shows 157,472 shares held directly.
How many AORT shares does Ackerman hold after this filing?
The filing shows 157,472 shares held directly after the reported transactions. Form 4 reports only the positions it lists, so this may not be every holding.
What does transaction code A mean on an SEC Form 4?
Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
Historical context for AORT
Across the 13 sessions after earlier AORT headlines, the stock closed higher 8 times and lower 4 times, with a median move of 2.1% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | AORT | SPY |
|---|---|---|---|
| May 18, 2026 | Endospan Announces Closing of Acquisition by Artivion, Inc., Following FDA PMA Approval of the NEXUS® Aortic Arch Systemand 1 other headline that session | +4.3% | -0.1% |
| May 8, 2026 | Artivion Reports First Quarter 2026 Financial Results and Announces Exercise of Option to Acquire Endospan | -28.3% | +0.8% |
| Apr 24, 2026 | Artivion Announces Release Date and Teleconference Call Details for First Quarter 2026 Financial Results | +1.6% | +0.8% |
| Apr 10, 2026 | Artivion upgraded by Ladenburg Thalmann with a new price target | +3.1% | -0.1% |
| Apr 7, 2026 | Artivion Announces U.S. FDA Approval of the NEXUS® Aortic Arch System | +5.3% | +0.0% |
| Mar 4, 2026 | Artivion to Participate in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference | -0.3% | +0.7% |
Earlier insider filings at AORT
- May 20, 2026Director Borgstrom Marna P was granted 7,850 shares, increasing direct ownership by 16% to 56,938 units (SEC Form 4)
- Mar 4, 2026VP, Chief Accounting Officer Horton Amy sold $34,036 worth of shares (901 units at $37.78) and was granted 7,475 shares, increasing direct ownership by 5% to 139,088 units (SEC Form 4)
- Mar 4, 2026SVP, General Counsel Holloway Jean F was granted 27,795 shares and sold $485,728 worth of shares (12,805 units at $37.93), increasing direct ownership by 9% to 185,095 units (SEC Form 4)
- Mar 4, 2026SVP, Clinical & MD Affair Stanton Marshall S. was granted 21,838 shares and sold $81,180 worth of shares (2,149 units at $37.78), increasing direct ownership by 49% to 60,097 units (SEC Form 4)
- Mar 4, 2026Chief Commercial Officer Davis John E was granted 28,845 shares and sold $172,748 worth of shares (4,573 units at $37.78), increasing direct ownership by 12% to 230,794 units (SEC Form 4)
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
Follow AORT and get a push notification the moment its next story breaks.